HUP0004271A3 - Compositions comprising amylin or amylin agonist for treating obesity - Google Patents

Compositions comprising amylin or amylin agonist for treating obesity

Info

Publication number
HUP0004271A3
HUP0004271A3 HU0004271A HUP0004271A HUP0004271A3 HU P0004271 A3 HUP0004271 A3 HU P0004271A3 HU 0004271 A HU0004271 A HU 0004271A HU P0004271 A HUP0004271 A HU P0004271A HU P0004271 A3 HUP0004271 A3 HU P0004271A3
Authority
HU
Hungary
Prior art keywords
amylin
compositions
treating obesity
agonist
amylin agonist
Prior art date
Application number
HU0004271A
Other languages
English (en)
Original Assignee
Amylin Pharmaceuticals Inc San
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc San filed Critical Amylin Pharmaceuticals Inc San
Publication of HUP0004271A2 publication Critical patent/HUP0004271A2/hu
Publication of HUP0004271A3 publication Critical patent/HUP0004271A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0004271A 1997-06-06 1998-06-05 Compositions comprising amylin or amylin agonist for treating obesity HUP0004271A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/870,762 US7910548B2 (en) 1997-06-06 1997-06-06 Methods for treating obesity
PCT/US1998/011753 WO1998055144A1 (en) 1997-06-06 1998-06-05 Methods for treating obesity

Publications (2)

Publication Number Publication Date
HUP0004271A2 HUP0004271A2 (hu) 2001-05-28
HUP0004271A3 true HUP0004271A3 (en) 2001-08-28

Family

ID=25356022

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004271A HUP0004271A3 (en) 1997-06-06 1998-06-05 Compositions comprising amylin or amylin agonist for treating obesity

Country Status (10)

Country Link
US (1) US7910548B2 (hu)
AU (1) AU7823098A (hu)
BR (1) BR9809951A (hu)
CZ (1) CZ294983B6 (hu)
HU (1) HUP0004271A3 (hu)
NO (1) NO324818B1 (hu)
NZ (1) NZ501451A (hu)
PL (1) PL193236B1 (hu)
RU (2) RU2207871C2 (hu)
WO (1) WO1998055144A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
AU760609B2 (en) * 1998-01-09 2003-05-15 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
JP2007525495A (ja) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286837A3 (en) † 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
CA2617649A1 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US20100249370A1 (en) * 2007-06-29 2010-09-30 Lonza Ag Process for the production of pramlintide
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
RU2552221C2 (ru) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
RU2523558C2 (ru) * 2012-08-22 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Россиской Федерации Способ лечения и повышения качества жизни больных с синдромом диспепсии в сочетании с ожирением
JP6769984B2 (ja) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ アミリン類似体
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN116018156A (zh) * 2020-04-20 2023-04-25 I2O治疗公司 使用人类胰淀素类似物多肽对1型糖尿病患者提供卓越的血糖控制

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443619A (en) * 1978-12-26 1984-04-17 Hoffmann-La Roche Inc. Chlorocitric acids
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
DE69022501T2 (de) * 1989-07-10 1996-02-01 Amylin Pharmaceuticals Inc Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten.
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
AU7691291A (en) * 1990-05-02 1991-11-27 Upjohn Company, The Method of treating gastric ulcers and obesity
SE466130B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
ATE157010T1 (de) 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
SK88793A3 (en) 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
AU656462B2 (en) * 1992-01-21 1995-02-02 Abbott Laboratories 4"-deoxyerythromycin derivatives
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
AU669636B2 (en) * 1993-05-12 1996-06-13 University Of Cincinnati, The Amylin antagonists and agonists
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
HUT76135A (en) * 1994-04-14 1997-06-30 Glaxo Wellcome Inc Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5646040A (en) * 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Also Published As

Publication number Publication date
NO995996L (no) 2000-02-07
HUP0004271A2 (hu) 2001-05-28
RU2314121C2 (ru) 2008-01-10
WO1998055144A1 (en) 1998-12-10
NZ501451A (en) 2001-10-26
BR9809951A (pt) 2000-08-01
NO995996D0 (no) 1999-12-06
US20030026812A1 (en) 2003-02-06
PL338082A1 (en) 2000-09-25
NO324818B1 (no) 2007-12-10
PL193236B1 (pl) 2007-01-31
CZ9904360A3 (cs) 2000-10-11
CZ294983B6 (cs) 2005-04-13
US7910548B2 (en) 2011-03-22
RU2207871C2 (ru) 2003-07-10
AU7823098A (en) 1998-12-21
RU2314121C9 (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
HUP0004271A3 (en) Compositions comprising amylin or amylin agonist for treating obesity
GB9607897D0 (en) Organosiloxane compositions
HUP9903759A3 (en) Abtimicrobial compositions
EP0994183A4 (en) FUNCTIONAL COMPOSITIONS
HK1031174A1 (en) Compositions and methods for treating diabetes
EP1015014A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS
EP0747443A3 (en) Organosiloxane compositions
HK1020215A1 (en) Electronic apparatus having improved heat-singing property.
GB9726814D0 (en) Compositions
GB9809058D0 (en) Composition
GB9702238D0 (en) Compositions
ZA981600B (en) Methods and compositions for treating stickies
GB9812119D0 (en) Composition
IL130856A0 (en) Peroxetine compositions
HUP0101867A3 (en) Installation for treating remaining material
GB9806788D0 (en) Composition
GB9828084D0 (en) Femoral component
GB9806793D0 (en) Composition
GB9828085D0 (en) Femoral component
PL342098A1 (en) Pharmacological compositions for treating diskineses
GB9804041D0 (en) Composition
GB9703553D0 (en) Process for making siloxane compositions
GB9705340D0 (en) Compositions
GB9703109D0 (en) Compositions
GB9806791D0 (en) Composition

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTRAZENECA PHARMACEUTICALS LP, US

Free format text: FORMER OWNER(S): AMYLIN PHARMACEUTICALS, INC., US; AMYLIN PHARMACEUTICALS, LLC, US

Owner name: AMYLIN PHARMACEUTICALS, LLC, US

Free format text: FORMER OWNER(S): AMYLIN PHARMACEUTICALS, INC., US; AMYLIN PHARMACEUTICALS, LLC, US

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished